In advanced non-small cell lung cancer (NSCLC), Next-Generation Sequencing (NGS) testing rates improved from 89% to nearly 100% after implementing an AI tool offering insights and tips, revealed Dr. Brian P. Mulherin, an oncologist at Hematology Oncology of Indiana. He highlighted the importance of overcoming barriers to NGS access, particularly through AI solutions that mitigate insurance issues. While guidelines recommend NGS for patients with metastatic diseases and advanced solid tumors, low testing rates persist in conditions like hormone receptor-positive breast cancer, where molecularly targeted therapy is critical. The AI-driven initiative, TIPS, identifies patients who have not received NGS and communicates this through various platforms, including Electronic Medical Records. This approach has successfully raised testing rates from 87.34% to 99.41% in advanced NSCLC patients at AON within seven months. Such advancements underscore the significance of enhancing patient access to necessary genomic testing.
Source link
